Daridorexant
DORA (Dual Orexin Receptor Antagonist), Hypnotic
Daridorexant
Quviviq
Daridorexant (brand name Quviviq) is a dual orexin receptor antagonist (DORA) approved by the FDA in 2022 for adults with insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Unlike benzodiazepines or Z-drugs, it does not enhance GABAergic transmission; instead it blocks the wake-promoting orexin/hypocretin system.
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Pharmacy
Starting dose
25 mg PO at bedtime; may increase to 50 mg if needed
Preparations
25 mg, 50 mg tablets
US FDA Max
50 mg/d
Common uses
Classification(s)
Classes
DORA (Dual Orexin Receptor Antagonist), Hypnotic
Pharmacology
Routes
Oral
Onset
~30 min
Duration
~7–8 h
Half-life
~8 h
Bioavailability
~62%
Pregnancy
Limited data; avoid
Legal status
Rx, Schedule IV (US)
Purported mechanism
Selective dual antagonist at OX1R and OX2R orexin receptors; reduces wake drive without GABAergic effects